358 Ramucirumab in combination with pembrolizumab as first-line treatment for recurrent or metastatic head and neck squamous-cell carcinoma: a phase 1–2 trial

作者
Douglas Adkins,Jessica Ley,Kevin Palka,Miriam T. Jacobs,Jingxia Liu,Peter Oppelt
出处
期刊:Journal for ImmunoTherapy of Cancer [BMJ]
卷期号:9
标识
DOI:10.1136/jitc-2021-sitc2021.358
摘要

Background VEGF, a key mediator of angiogenesis and resistance to immunotherapy, is overexpressed in head and neck squamous-cell carcinoma (HNSCC). The primary aims of this trial were to determine the recommended phase 2 dose (RP2D) of ramucirumab, a potent inhibitor of VEGF receptor-2, given with pembrolizumab, and the objective response rate (ORR) of this combination as first-line treatment for recurrent or metastatic (RM)-HNSCC. Methods Study participants provided written informed consent. Eligible patients had incurable HNSCC originating in the oral cavity, oropharynx, larynx, or hypopharynx. RM disease within 6 months of curative-intent systemic therapy and programmed death ligand (PD-L1) negative disease were permitted. In a dose de-escalation phase 1 design, patients received ramucirumab (level one: 10 mg/kg; then 8 and 6 mg/kg) and pembrolizumab (200 mg) on day 1 of each 21-day cycle until discontinuation criteria were met. Each dose level included three patients. The RP2D of ramucirumab was defined as the highest dose level at which one or fewer patients experienced a dose-limiting toxicity (DLT) during cycle one. In a Simon two-stage phase 2 design, patients with measurable, previously untreated RM-HNSCC received ramucirumab at the RP2D with pembrolizumab. Tumor response was assessed by RECIST1.1. When the trial was developed, the ORR of pembrolizumab given as first-line treatment wasn’t known; however, the ORR for platinum pre-treated disease was 13–18%. Therefore, an ORR of 32% was of clinical interest. In stage one, two or more responses among ten patients were required to enroll to stage two. Eight or more responses among 33 evaluable patients (those with at least one response assessment) was evidence for efficacy (80% power; one-sided α= 0.05). Results Three patients were treated in phase 1 and 37 in phase 2. Eleven patients (28%) had recurrent disease within 6 months of curative-intent systemic therapy. In phase 1, no DLT occurred at the starting dose of ramucirumab. Tumor response occurred in 2 of these 3 patients. In phase 2, tumor response occurred in 19 of 33 evaluable patients (ORR 57.6%, 95%CI: 39.2–74.5). Tumor response by PD-L1 CPS is shown in the table below (table 1). No unexpected safety concerns were identified. Conclusions The RP2D of ramucirumab given with pembrolizumab was 10 mg/kg on day 1 of each 21-day cycle. The primary hypothesis was accepted: the ORR with ramucirumab and pembrolizumab was higher than expected with pembrolizumab monotherapy when given as first-line treatment for RM-HNSCC. Trial Registration This trial is registered with ClinicalTrials.gov (NCT03650764). Ethics Approval This study was approved by Washington University’s Ethics Board; approval number 201809094.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
香蕉寄云完成签到,获得积分10
刚刚
xrxrxr完成签到,获得积分10
刚刚
妙蛙完成签到 ,获得积分10
刚刚
Cynn发布了新的文献求助30
1秒前
1秒前
we发布了新的文献求助10
1秒前
tkyy完成签到,获得积分10
1秒前
白学完成签到,获得积分10
1秒前
lia完成签到 ,获得积分10
1秒前
英姑的应助被温暖元柏采纳,获得10
2秒前
2秒前
2秒前
2秒前
2秒前
3秒前
科研通AI6.4的应助被不管啦采纳,获得30
3秒前
Ava的应助被背后的大门采纳,获得10
3秒前
Robby完成签到 ,获得积分10
3秒前
3秒前
li完成签到,获得积分10
3秒前
彭于彦祖的应助被炸鸡柳大王采纳,获得30
3秒前
ZHANG发布了新的文献求助50
3秒前
一蓑烟雨完成签到 ,获得积分10
3秒前
希望天下0贩的0的应助被柠柠采纳,获得10
3秒前
liujianxin完成签到,获得积分20
4秒前
沉静的成危完成签到,获得积分10
4秒前
4秒前
英姑的应助被刘兆亮采纳,获得10
4秒前
Lucia发布了新的文献求助10
4秒前
小鲸鱼完成签到,获得积分10
4秒前
mmnn完成签到 ,获得积分10
5秒前
5秒前
江舁完成签到 ,获得积分10
5秒前
清脆的初蝶完成签到,获得积分10
5秒前
谢老师发布了新的文献求助10
6秒前
6秒前
6秒前
6秒前
6秒前
冷静幻枫完成签到,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180713
求助须知:如何正确求助?哪些是违规求助? 9570752
关于积分的说明 21814119
捐赠科研通 7776960
什么是DOI,文献DOI怎么找? 3433298
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479287